Introduction {#S1}
============

Coronaviruses (CoVs) were first identified in 1960 ([@B108]) and were classified as members of the family *Coronaviridae*. CoVs are enveloped, single-stranded RNA viruses with a genome varying from 25 to 32 kb ([@B161]). The viral structure is primarily formed by the structural spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. The S, M, and E proteins are embedded in the viral envelope, which is a lipid bilayer derived from the host cell membrane. The N protein, on the other hand, interacts with the viral RNA into the core of the virion ([Figure 1](#F1){ref-type="fig"}; [@B67]).

![Schematic structure of SARS-CoV-2. The viral structure is primarily formed by the structural proteins such as spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. The S, M, and E proteins are all embedded in the viral envelope, a lipid bilayer derived from the host cell membrane. The N protein interacts with the viral RNA in to the core of the virion.](fmicb-11-01818-g001){#F1}

These viruses can infect vertebrate animals, causing acute to chronic diseases in the respiratory, cardiac, enteric, and central nervous systems, both in animals and humans ([@B237]). In animals, the most common CoVs are infectious bronchitis virus (IBV), feline CoV (FeCoV), and mouse hepatitis virus (MHV), which infect chickens, felines, and rodents, respectively ([@B50]). To date, there are seven known CoVs that cause diseases in humans: HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and, most recently, SARS-CoV-2 ([@B79]; [@B28]). The CoVs HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1 cause mild symptoms, similar to a common cold ([@B161]). However, SARS-CoV, MERS-CoV, and SARS-CoV-2 can cause mild to severe symptoms related to upper respiratory infection such as fever, cough, dyspnea, pneumonia, and acute respiratory distress syndrome (ARDS), ultimately leading to death ([@B122]). The severe clinical condition generated especially by SARS-CoV-2 has been burdening public health systems worldwide ([@B96]), evidencing the mandatory need for further research encompassing antiviral treatment against CoVs, which has somehow, until recently, been relatively ignored by broad pharmaceutical and medicinal fields ([@B138]; [@B50]).

CoVs are linked to a zoonotic transmission due to their ability to infect different species. This can lead to host jumps, allowing the emergence of new coronaviruses such as SARS-CoV, MERS-CoV, and SARS-CoV-2 ([@B138]; [@B180]; [@B11]). The transmission of CoVs is based on the fecal-oral route in animals ([@B118]). In humans, CoV transmission occurs by direct contact with droplets when infected and recipient individuals are in close contact (about one meter). These infectious oral and respiratory droplets produced by talking, coughing, sneezing need to contact the mucosae (mouth and nose) or conjunctiva (eyes) of the recipient person. Additionally, indirect transmission can occur by touching a surface with viable CoV and subsequent contact with mouth, nose, or eyes ([@B224]). Viral particles may remain viable on surfaces for several days, increasing the probability of infection by third parties ([@B224]).

Recently, the emergence of SARS-CoV-2 was related to zoonotic transmission, but it is still not clear how this virus was first transmitted to humans ([@B11]; [@B77]). By phylogenetic analysis, the SARS-CoV-2 was grouped within bat SARS-related coronaviruses, suggesting that a host jump occurred ([@B26]; [@B122]). Alarmingly, the high transmissibility of this new CoV allowed the rapid and efficient spread of the virus across the world so that it became a pandemic disease in just a few months ([@B28]; [@B246]).

Due to the novelty of this disease, there is a lack of understanding of the SARS-CoV-2 replication process in host cells. The general mechanisms of entry into the host cell, replication, and release follow characteristics that have been described for other CoVs and have been partially confirmed for SARS-CoV-2. To date, it is known that the SARS-CoV-2 virion entries the host cells by the attachment of the S protein with angiotensin-converting enzyme 2 receptor (ACE2), defining SARS-CoV-2 tropism for cells that express this receptor, such as pulmonary, hepatic, gastrointestinal, and renal human cells ([@B44]; [@B93]; [@B210]). The interaction of ACE2 with the receptor-binding domain (RBD) of the S protein triggers virion endocytosis and the formation of an endosome ([@B175]). The S protein possesses two subunits, S1 and S2 ([@B230]). During endocytosis, an acid-dependent proteolytic cleavage of the S1 protein by cellular proteases, like cathepsin, TMPRRS2, and trypsin, exposes the S2 subunit, a fusion peptide that allows the fusion of the viral envelope with the endosome membrane, and consequently, releases the capsid into the cell cytoplasm ([@B20]; [@B143]). In the cytoplasm, the CoV viral genome is uncoated, and the viral RNA is released. The positive-sense RNA viral genome is translated to produce nonstructural proteins (nsps) from two open reading frames (ORFs), ORF1a and ORF1b. The ORF1a encodes the polyprotein pp1a that is cleaved in 11 nsps, while the ORF1b encodes the polyprotein pp1ab, which is cleaved into 15 nsps. The proteolytic cleavage is performed by viral proteases nsp3 and nsp5 ([@B252]; [@B123]; [@B114]). The nsps assemble to form a replicase-transcriptase complex (RTC) responsible for RNA synthesis, replication, and transcription of nine subgenomic RNAs (sgRNAs) ([@B67]; [@B37]; [@B114]). The sgRNAs act as mRNAs for structural and accessory genes localized downstream of the replicase polyproteins. SARS-CoV-2 has six accessory proteins: 3a, 6, 7a, 7b, 8, and 10 ([@B114]). The structural proteins S, E, and M are translated from the sgRNAs and forwarded to the endoplasmic reticulum (ER) and are subsequently inserted into an intermediate compartment of ER with Golgi (ERGIC). There, viral genomes are encapsulated by N proteins and assembled with the structural proteins to form virions ([@B204]; [@B67]; [@B132]). The M proteins bind to E protein and nucleocapsid, and then, the S protein is incorporated, forming a complete virion. Finally, the virions are transported to the cell surface in vesicles and released in a pathway mediated by exocytosis ([Figure 2](#F2){ref-type="fig"}; [@B67]; [@B114]; [@B132]).

![Schematic representation of SARS-CoV-2 replication cycle in host cells. SARS-CoV-2 attaches to the host cells by interaction between the ACE2 receptors and spike proteins. After entry, viral uncoating process results in the release of viral genome and replication stage occurs (translation and transcription). Structural proteins are produced in intermediate compartment of endoplasmic reticulum with Golgi complex and forwarded to assembly, packaging and virus release. Compounds with antiviral activity against SARS-CoV-2 are indicated in each step of virus replication cycle.](fmicb-11-01818-g002){#F2}

It is important to emphasize that SARS-CoV-2 shows different epidemiological and clinical features from the epidemics of SARS-CoV and MERS-CoV ([@B30]; [@B76], [@B77]). The high transmissibility of SARS-CoV-2 may be related to its entry into host cells ([@B209]). Although both SARS-CoV and SARS-CoV-2 glycoprotein S attach to ACE2 to enter the host cells, the binding affinity of SARS-CoV-2 is higher, thus enhancing its infectivity ([@B209]; [@B248]). Despite the relative homology between S1 and S2 amino acid sequences, a 1.2 Å root-mean-square deviation at the 417 position ([@B139]) of S2 protein in SARS-CoV-2 may be related to its higher infectiveness, contributing to a 10- to 20-fold higher kinetic affinity of SARS-CoV-2 ectodomain, as evidenced by Wrapp and co-workers, employing surface plasmon resonance measurements ([@B244]).

Considering the particularities of SARS-CoV-2 and the emergency caused by its outbreak, several strategies have been adopted to develop therapeutics and prophylactic measures against this virus. The strategies employed in these developments include: (i) utilization of bioinformatics for the prediction and investigation of potential ligands toward target molecules in the viral structure and/or replication ([@B5], 2; [@B105], 2); (ii) employment of cell culture systems, permissive to CoVs ([@B22]; [@B137]), associated with pseudo particles, subgenomic replicons and/or full-length CoVs, seeking to assess cellular response or the effects of the compounds on the viral replicative cycle ([@B182]; [@B93]); (iii) the use of animal models, such as mice, mouse, guinea pig, hamster and non-human primates, for evaluating therapeutic options or antibody production in immunization ([@B157]; [@B199]), and (iv) clinical trials assessing the administration, distribution, metabolism, and toxicity profiles (ADMeTox) of potential therapeutics as well as immunization effects in humans ([@B47]).

Based in previous results in vaccine development for MERS-CoV and SARS-CoV and the similarity of those viruses with SARS-CoV-2 ([@B61]), the current vaccine candidates are more focused on the S protein, since is a major inducer of neutralizing antibodies in infected patients ([@B230]). For this reason, efforts are concentrated on using approaches such as mRNA, DNA, viral vectors, or virus-like particles vaccines with a full-length S protein or S1 receptor-binding domain (RBD) to stimulate immune response and immunization ([@B5]; [@B33]). The most promising vaccines are: (i) adenovirus-vectored AZD1222 produced by Oxford University ([@B217]), a vaccine that is currently in clinical phase 3, being tested in several countries, including the United States, Brazil, and countries in Asia and Africa; (ii) mRNA-1273 associated with a lipidic nanoparticle (NCT04283461), which is currently in clinical phase 2; and (iii) inactivated virus vaccine, which is currently in clinical phase 1 ([@B153]; [@B220]).

The high transmissibility and viral variability of the novel SARS-CoV-2, along with the lack of a vaccine or drugs to treat the infected patients, threaten the global health system. In this context, the development of effective antivirals is critical to provide short-term therapies able to reduce the severity of clinical outcomes of coronavirus disease 2019 (COVID-19) and to reduce the spread of SARS-CoV-2. Here, we summarize compounds described, from 2005 to date, to possess antiviral activity *in vitro* and/or *in vivo* against CoVs and critically compare molecules that could be further investigated by their clinical applicability ([Table 1](#T1){ref-type="table"}). We also discuss the compounds that have reached clinical trials ([Table 2](#T2){ref-type="table"}) as well as the potentiality of other molecules for application in (re)emergent CoVs outbreaks. Finally, we aim to encourage further research encompassing these compounds as potential SARS-CoV-2 drug candidates.

###### 

Compounds with antiviral activity against human and animal coronaviruses.

  Compound                                                       Inhibition step                    EC50 or inhibition (%)     CoVs                         Advantges and/or limitations                                                                                                                                           References
  -------------------------------------------------------------- ---------------------------------- -------------------------- ---------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------
  NAAE                                                           Entry                              0.5 μM                     SARS-CoV                     Synthetic molecule, evaluated *in silico*, easily produced but lacks *in vivo* assays                                                                                  [@B99]
  Glycyrrhizin                                                   Entry                              300 mg L^--1^              SARS-CoV                     Natural molecule, highly tolerated but lacks *in vivo* assays                                                                                                          [@B46]
  2-acetamido-α-[D]{.smallcaps}-Glucopyranosylamine derivative   Entry                              40 μM                      SARS-CoV                     Semi-synthetic molecule, highly tolerated, and more potent inhibitor but lacks *in vivo* assays                                                                        [@B92]
  Tetrahydroquinoline oxocarbazate (CID 23631927)                Entry (Cathepsin L)                273 nM                     SARS-CoV                     Synthetic molecule, highly tolerated, easily produced but lacks *in vivo* assays                                                                                       [@B194]
  SSAA09E1                                                       Entry                              6.7 μM                     SARS-CoV                     Synthetic molecule, highly tolerated, easily produced but lacks *in vivo* assays                                                                                       [@B2]
  SSAA09E2                                                       Entry                              3.1 μM                     SARS-CoV                     Synthetic molecule, highly tolerated, easily produced but lacks *in vivo* assays                                                                                       [@B2]
  SSAA09E3                                                       Entry                              9.7 μM                     SARS-CoV                     Synthetic molecule, highly tolerated, easily produced but lacks *in vivo* assays                                                                                       [@B2]
  Emodin                                                         Entry and Post-Entry               50 μM                      SARS-CoV                     Natural molecule, highly tolerated but lacks *in vivo* assays                                                                                                          [@B91]; [@B193]
  Griffithsin (GRFT)                                             Entry                              0.16 μg mL^--1^            HCoV-OC43                    Natural molecule, highly tolerated, with a broad-spectrum effect (human and animal CoVs); protected against infection and improved survival in animal assay (Balb/c)   [@B158]
                                                                 Entry                              0.18 μg mL^--1^            HCoV-229E                                                                                                                                                                                           
                                                                 Entry                              0.61 μg mL^--1^            SARS-CoV                                                                                                                                                                                            
                                                                 Entry                              \<0.032 μg mL^--1^         HCoV-NL63                                                                                                                                                                                           
                                                                 Entry                              0.057 μg mL^--1^           BCoV                                                                                                                                                                                                
                                                                 Entry                              0.23 μg mL^--1^            MHV                                                                                                                                                                                                 
  Eremomycin derivate 27                                         Entry                              5.4 μM                     FIPV                         The precursor molecule (Eremomycin) is used to treat bacterial infections; may facilitate clinical assays, but knowledge of the mechanism of action is lacking         [@B15]
                                                                 Entry                              14 μM                      SARS-CoV                                                                                                                                                                                            
  Eremomycin derivate 39                                         Entry                              12 μM                      FIPV                                                                                                                                                                                                
                                                                 Entry                              22 μM                      SARS-CoV                                                                                                                                                                                            
  Mucroporin-M1                                                  Entry                              14.46 μg mL^--1^           SARS-CoV                     Synthetic molecule, moderately tolerated, easily produced but lacks *in vivo* assays                                                                                   [@B131]
  Tyr-Lys-Tyr-Arg-Tyr-Leu                                        Entry                              14 mM                      SARS-CoV                     Synthetic molecule specifically designed to bind S protein of SARS-CoV; highly tolerated, does not impair ACE2 activity but lacks *in vivo* assays                     [@B208]
                                                                 Entry                              14 mM                      HCoV-NL63                                                                                                                                                                                           
  TAPI-2                                                         Entry                              65%                        SARS-CoV                     Good effects in vitro assays but had no effect on *in vivo* assays                                                                                                     [@B84]
  Monoclonal antibody 47D11                                      Entry                              0.57 μg mL^--1^            SARS-CoV-2                   Human antibody, specifically to SARS-CoV-2, highly tolerated and easily applicable                                                                                     [@B231]
  AVLQSGFR                                                       Replication                        2.7 × 10^--2^ mg mL^--1^   SARS-CoV                     Synthetic molecule, highly tolerated, easily produced but lacks *in vivo* assays                                                                                       [@B69]
  Phe-Phe dipeptide inhibitor C (JMF1521)                        Replication                        0.18 μM                    SARS-CoV                     Synthetic molecule, highly tolerated, easily produced but lacks *in vivo* assays                                                                                       [@B202]
  Dipeptidyl EP128533                                            Replication                        3.6 μM or 1.4 μg mL^--1^   SARS-CoV                     Synthetic molecule, highly tolerated, easily produced but has contrasting effects in the literature and did not inhibit the virus in *in vivo* assays                  [@B256]; [@B55]
  GC373                                                          Replication                        0.2 μM                     HCoV-229E                    Synthetic molecule, highly tolerated, easily produced, seems to interact with SARS-CoV 3CLpro, but there are no *in vivo* assays                                       [@B115], [@B116]
                                                                                                    0.3 μM                     FIPV                                                                                                                                                                                                
                                                                                                    2 μM                       MHV                                                                                                                                                                                                 
                                                                                                    0.3 μM                     TGEV                                                                                                                                                                                                
                                                                                                    0.7 μM                     BCV                                                                                                                                                                                                 
                                                                                                    0.15 μM                    FCoV-WSU                                                                                                                                                                                            
  GC376                                                          Replication                        0.15 μM                    HCoV-229E                    Synthetic molecule, highly tolerated, easily produced, seems to interact with SARS-CoV 3CLpro, but there are no *in vivo* assays                                       [@B115], [@B116]
                                                                                                    0.2 μM                     FIPV                                                                                                                                                                                                
                                                                                                    1.1 μM                     MHV                                                                                                                                                                                                 
                                                                                                    0.15 μM                    TGEV                                                                                                                                                                                                
                                                                                                    0.6 μM                     BCV                                                                                                                                                                                                 
                                                                                                    0.40 μM                    FCoV-WSU                                                                                                                                                                                            
  6-azauridine                                                   Replication                        32 nM                      HCoV-NL63                    Synthetic molecule, highly tolerated, easily produced, but there are no *in vivo* assays                                                                               [@B174]
  2-(benzylthio)-6-oxo-4-phenyl-1,6-dihydropyrimidine            Replication                        NE                         SARS-CoV                     Synthetic molecule, highly tolerated, easily produced, but there are no in vivo assays                                                                                 [@B176]
  β-[D]{.smallcaps}-N^4^-hydroxycytidine                         Replication                        10 μM                      SARS-CoV                     Synthetic molecule, highly tolerated, easily produced, and improved pulmonary function and decreased viral load in lung of infected mice                               [@B17]; [@B199]
                                                                 Replication                        400 nM                     HCoV-NL63                                                                                                                                                                                           
                                                                 Replication                        0.08--0.3 μM               SARS-CoV-2                                                                                                                                                                                          
                                                                 Replication                        0.024 μM                   MERS-CoV                                                                                                                                                                                            
  Ribavirin                                                      Replication                        20 μg mL^--1^              SARS-CoV                     Synthetic molecule, highly tolerated, easily produced, good results in MERS-CoV. However, meta-analyses indicate limited efficacy.                                     [@B187]; [@B16]
  Acyclic sugar scaffold of acyclovir                            Replication                        23 μM                      MERS-CoV                     Synthetic molecule, highly tolerated, easily produced, but there are no *in vivo* assays                                                                               [@B163]
                                                                                                    8.8 μM                     HCoV-NL63                    Synthetic molecule, highly tolerated, derivate from Acyclovir, easily produced, but there are no in vivo assays                                                        
  Niclosamide                                                    Replication                        0.1 μM                     SARS-CoV                     Drug already in use to treat helminthic infections; good inhibition *in vitro*                                                                                         [@B245]; [@B238]
  Mycophenolic acid (MPA)                                        Replication                        2.87 μM                    MERS-CoV                     Good effects *in vitro* with MERS-CoV but did not inhibit SARS-CoV in *in vitro* and *in vivo* assays                                                                  [@B46]; [@B16]; [@B87]
  TP29 peptide                                                   Replication                        60 μM                      MHV                          Inhibited two species of CoV in mice; also improved survival and induced INF-I. Inhibited CoV in cell lines. Synthetic compound designed for nonstructural proteins.   [@B235]
                                                                 Replication                        200 μM                     SARS-CoV                                                                                                                                                                                            
  Bananins                                                       Replication                        \<10 μM                    SARS-CoV                     Synthetic molecule, highly tolerated, easily produced, but there are no *in vivo* assays                                                                               [@B214]
  Nitazoxanide                                                   Host Enzymes                       0.92 μg mL^--1^            MERS-CoV                     Drug already in use to treat viral infections; good inhibition *in vitro*                                                                                              [@B185]
  Tizoxanide                                                     Host Enzymes                       0.83 μg mL^--1^            MERS-CoV                     Drug derived from Nitazoxanide; good inhibition *in vitro*                                                                                                             [@B185]
  Saracatinib                                                    Tyrosine Kinases                   2.9 μM                     MERS-CoV                     Synthetic molecule, highly tolerated, used to treat Alzheimer's disease and easily produced but there are no in vivo assays                                            [@B203]
  Cyclosporin A (CsA)                                            Hosts Cyclophilin Family Enzymes   9--32 μM                   SARS-CoV, MERS-CoV and MHV   Drug already used to treat several chronic and infectious diseases with broad-spectrum activity among CoVs                                                             [@B59], [@B58]; [@B165]
  Alisporivir                                                    Hosts Cyclophilin Family Enzymes   8.3 μM                     SARS-CoV                     Analog of CsA and has a strong inhibition *in vitro* against SARS-CoV and other CoVs                                                                                   [@B56]
  Interference RNA (iRNAs)                                       Viral Proteins Translation         70%                        SARS-CoV                     Different approach, specific targeting of viral proteins; can block replication steps and has no cytotoxicity                                                          [@B6]
                                                                 Viral Proteins Translation         99%                        SECoV                        Different approach, specific targeting of viral proteins; can block replication steps and has no cytotoxicity                                                          [@B130]

EC50: effective concentration of 50%; NE: not evaluated.

###### 

Ongoing clinical trials of candidate drugs against SARS-CoV-2 in COVID-19 patients.

  Drug                               Cell culture assays                                     Inhibition step *in vitro*                   Animal assays                                                   Clinical trials                                                                      Outcomes in clinical trials                                                                                                                                                                                                  Advantages and/or limitations
  ---------------------------------- ------------------------------------------------------- -------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Remdesivir                         Inhibited SARS-CoV, MERS-CoV, and SARS-CoV-2            Replication (RdRp)                           Inhibited EBOV and SARS-CoV in both infected mice and monkeys   Clinical case and clinical trial against SARS-CoV-2                                  Did not provide antiviral effects or improved clinical outcomes                                                                                                                                                              This is a multicentre, double-blind, placebo-controlled clinical trial, but more studies might be needed to confirm, since this includes 255 people, and the drug has some adverse effects.
  Lopinavir and Ritonavir            Inhibited SARS-CoV and MERS-CoV                         Replication (protease inhibitor)             NE                                                              Clinical trial with SARS-CoV-2                                                       Did not provide antiviral effects or improved clinical outcomes in severe patients, but, in early infections, clinical outcomes were improved.                                                                               This drug combination is used for other human CoVs, but the study was not multicentre, double-blind, and placebo-controlled. More studies are necessary to confirm, since it had only 199 people and the drug showed some adverse effects.
  IFN-β                              Inhibited SARS-CoV, MERS-CoV, MHV, and HCoV-229E        Host Factors (inducing immune response)      Inhibited SARS-CoV, MERS-CoV, MHV, and HCoV-229E                Clinical trial with SARS-CoV-2 and is used for other diseases                        Do not have effect alone                                                                                                                                                                                                     IFN-β is indicated to be safe, with few adverse effects, but in clinical trials, it is only effective when associated with other drugs.
  Umifenovir                         Inhibited SARS-CoV                                      NE                                           NE                                                              Observational study with 81 patients                                                 Did not provide antiviral effects or improved clinical outcomes                                                                                                                                                              This is an observational study and might suffer bias from lack and/or loss of information and data. It is an applicable study, since it demonstrates a tendency, and the drug is already used to treat Influenza viruses.
  Corsticosteroids (dexamethasone)   NE                                                      Host factors (controlling immune response)   NE                                                              Clinical trial with 454 treated patients                                             Reduced death by one-third in invasive mechanical ventilation patients and one-fifth in oxygen without invasive mechanical ventilation patients; however, did not impair mortality in patients without respiratory support   This is a multicentre, double-blind, placebo-controlled clinical trial. More studies are needed to understand better the effect on different phases of COVID-19. May be a good alternative for treating hyperinflammation and hypersecretion of cytokines.
  Ivermectin                         Inhibited SARS-CoV-2 and arboviruses (CHIKV and DENV)   Replication (nonstructural proteins)         NE                                                              Clinical trials are beginning                                                        NE                                                                                                                                                                                                                           Ivermectin is safe for use in humans since it is used to treat several parasitic infections.
  Tocilizumab                        NE                                                      Inhibitor of IL-6                            NE                                                              Ongoing clinical trials with SARS-CoV-2 patients; one with 100 patients concluded.   Positive effects: improved inflammatory markers and decreased the need for ventilatory support in patients                                                                                                                   Tocilizumab is already used to treat viral infections, controlling immune response, impairing cytokine storms, improving antiviral response, and providing the best clinical outcomes.
  Chloroquine                        Inhibited HIV, CHIKV, SARS-CoV, and SARS-CoV-2          Entry                                        Improved outcomes in FCoV positive cats                         Several clinical trials are being conducted                                          Impairs virus replication and has anti-inflammatory activities                                                                                                                                                               Chloroquine possesses important side effects and is indicated only in severe cases. However, there are some studies with contrasting results regarding its safety, since it can cause arrhythmias, hypoglycemia, neuropsychiatric effects, and depression.
  Hydroxychlo-roquine                Inhibited HIV, CHIKV, SARS-CoV, and SARS-CoV-2          Entry                                        NE                                                              Several clinical trials are being conducted                                          Less toxic option, impairs virus replication                                                                                                                                                                                 Hydroxychloroquine improved patients' outcomes, including when associated with azithromycin. Less toxic option than chloroquine treatment, but there are studies with contrasting results regarding its safety, since it can cause arrhythmias, hypoglycemia, neuropsychiatric effects, and depression.
  Convalescent Plasma                NE                                                      Entry                                        NE                                                              Case report                                                                          Improved outcomes and suppressed viremia.                                                                                                                                                                                    Administration poses a risk to patients since it is related to donor-dependent variability and compatibility. Antibody titers may interfere with its activity. In addition, it might cause side effects in lung and the cardiovascular system.

EC50: effective concentration of 50%; NE: not evaluated.

Inhibitors of the CoV Replicative Cycle {#S2}
=======================================

Inhibitors of CoV Entry Into Host Cells {#S2.SS1}
---------------------------------------

The entry of human CoVs into the host cells is mainly related to the binding of viral S protein to the ACE2 receptor ([@B166]; [@B209]). Therefore, it is reasonable to hypothesize that compounds affecting this interaction could be potential antivirals ([@B166]).

In this context, a survey encompassing *in silico* studies of more than 140 thousand potential S-protein-inhibiting drugs indicated that the molecule *N*-(2-aminoethyl)-1 aziridineethanamine (NAAE) showed the highest docking grade (-23.7 kcal/mol) ([@B99]). The activity of NAAE was further confirmed by employing an *in vitro* enzymatic inhibitory assay, using a human recombinant ACE2. In this assay, ACE2 removed the C-terminal dinitrophenyl moiety that quenched the inherent fluorescence of the 7-methoxycoumain group, increasing the fluorescence when ACE2 was active ([@B99]). The results showed that NAAE inhibited the ACE2 enzymatic activity with the half maximal inhibitory concentration (IC~50~) of 57 μmol mL^−1^ ([@B99]). In addition, 293T cells expressing ACE2 receptor were incubated with NAAE and then with S glycoprotein-expressing 293T cells, and measurement of β-galactosidase activity (reported gene in cell-cell fusion) was performed. NAAE at 0.5 μM inhibited 50% of SARS-CoVs spike protein-mediated cell fusion, suggesting that NAAE might be a candidate for treating SARS infection by impairing viral attachment via interference with ACE2 ([@B99]). However, a detailed explanation of how NAAE is a more efficient ligand to ACE2 than other compounds was not attempted by the authors.

Ramos-Tovar and Muriel reported the antiviral activity of Glycyrrhizin (GL), a major constituent from licorice root ([@B177]), which was able to inhibit SARS-CoV entry into Vero cells with an effective concentration of 50% (EC~50~) of 300 mg L^--1^ and a cytotoxicity concentration of 50% (CC~50~) of \>20.000 mg L^--1^. GL was less effective when the administration occurred during the viral adsorption period than when it was administered after entry into host cells. Cumulative effects were observed when this compound was administered both during and after entry into host cells, which indicates a significantly potent inhibitor against the virus under the tested conditions ([@B46]). Additionally, the antiviral activity of 15 GL derivates against SARS-CoV was assessed ([@B92]). Conjugation on both acidic moieties of the GL disaccharide group with 2-acetamido-α-[D]{.smallcaps}-glucopyranosylamine, benzylcysteine, and Gly-Leu peptide generated compounds with an increase of 10- to 70-fold in anti-SARS-CoV activity when compared to GL itself ([@B92]). For the case of 2-acetamido-α-[D]{.smallcaps}-glucopyranosylamine derivative, it was speculated that viral entry was inhibited through *N*-acetylglycosamine binding onto S-protein carbohydrates. Other derivatives such as the introduction of heterocyclic amides such as 6-amine-thiouracil induced a higher cytotoxicity profile.

The endossomal cathepsins are essential enzymes in viral entry into host cells ([@B97]), and cathepsin L has been pointed to as playing a crucial role in membrane fusion with the endosomes ([@B20]; [@B143]). In this context, Shah and coworkers demonstrated the effective activity of tetrahydroquinoline oxocarbazate (CID 23631927), an oxocarbazate inhibitor of cathepsin L, against SARS-CoV. Employing a pseudovirus system with a luciferase reporter to infect 293T cells, the compound inhibited viral entry with an EC~50~ of 273 ηM and CC~50~ \> 100 μM ([@B194]). The authors also showed that the compound CID 23631927 seems to bind with a lower inhibition constant (K~*i*~) to cathepsin L, improving the compound/cathepsin L interaction. This might be related to its optimized structure, with stronger hydrophobic interactions and better hydrogen bonds between the compound and cathepsin L ([@B194]).

An extensive study screened a library of compounds following Lipinski's rule ([@B135]) and identified three noncytotoxic compounds capable of inhibiting SARS-CoV pseudoparticle entry into 293T cells ([@B2]). *N*-(9,10-dioxo-9,10-dihydroanthracen-2-yl)benzamide (SSAA09E1) blocked early interactions of SARS-CoV S protein with ACE2 (EC~50~ of 6.7 μM and CC~50~ \> 100 μM), whereas *N*-\[\[4-(4-methylpiperazin-1-yl)phenyl\]methyl\]-1,2-oxazole-5-carboxamide (SSAA09E2) affected cathepsin L activity (EC~50~ of 3.1 μM and CC~50~ \> 100 μM). Conversely, \[(Z)-1-thiophen-2-ylethylideneamino\]thiourea (SSAA09E3) prevented the fusion of the viral envelope with host membrane cells by direct interaction with spike protein (EC~50~ of 9.7 μM and CC~50~ \> 20 μM) ([@B2]). The compound SSAA09E3 presented the highest cytotoxic, probably due to the interactions with host proteins. The authors suggested that since these three compounds are derived from molecules with antiviral activities and presented good oral bioavailability and rapid systemic distribution in animal models, they might exhibit interesting pharmacokinetics ([@B2]).

Other compounds also demonstrated to inhibit CoV entry, for example, emodin (6-methyl-1,3,8-trihydroxyanthraquinone), a component from *Rheum officinale* roots, which at 50 μM inhibited the infectivity of S protein-pseudotype retrovirus from SARS-CoV in Vero cells by about 80% ([@B91]). Besides the entry activity, emodin was described to have an additional post-entry antiviral action. The authors suggested that emodin might be impairing virus release by affecting 3a viral protein, which is related to ion channels in infected Vero cells ([@B193]). This effect may play an important role in immune response.

The exploitation of other natural compounds such as proteins as potential anti-CoV drugs has also been performed. Griffithsin (GRFT) is a protein isolated from the red alga *Griffithsia* sp. that has shown powerful viral entry inhibition against several enveloped viruses, such as the human immunodeficiency virus (HIV). GRFT is capable of binding to terminal mannoses of oligosaccharides and also to glycans localized on the viral envelope glycoproteins ([@B139]). GFRT did not present cytotoxicity in Vero cells, human ileocecal colorectal adenocarcinoma cells, human diploid fibroblast cells, and rhesus monkey kidney cells. Its broad-spectrum antiviral activity *in vitro* was demonstrated against several CoVs such as SARS-CoV (EC~50~ of 0.61 μg mL^−1^), bovine coronavirus (BCoV) (EC~50~ of 0.057 μg mL^--1^), MHV (EC~50~ of 0.23 μg mL^--1^), HCoV-OC43 (EC~50~ of 0.16 μg mL^--1^), HCoV-229E (EC~50~ of 0.18 μg mL^--1^), and HCoV-NL63 (EC~50~ \< 0.032 μg mL^--1^) ([@B158]). In another study, GRFT inhibited the early stages of MERS-CoV infection in HEK-293T cells ([@B148]). Furthermore, GRFT improved survival in SARS-CoV-infected mice and protected the Balb/c female mice against infection by binding with S protein ([@B158]). Altogether, this evidence indicates that GRFT can be considered as a potential SARS-CoV-2 entry inhibitor with activity against S proteins.

Antiviral activity by entry inhibition was also evaluated by employing antibacterial chemotherapeutics. Vancomycin, eremomycin, and teicoplanin glycopeptide compounds used to treat infections caused by Gram-positive bacteria ([@B167]), as well as hydrophobic derivatives of these drugs, were described to possess antiviral activity against HIV ([@B168]). A study showed that vancomycin, eremomycin, and teicoplanin were not toxic to Vero and T lymphoblast (CEM) cells. Nonetheless, these compounds were not able to inhibit feline CoV (FIPV) and SARS-CoV in assays employing such cell lines. Conversely, the eremomycin derivative molecules labeled 27 and 39 showed the best inhibition profiles against FIPV (EC~50~ of 5.4 and 12 μM, respectively) and SARS-CoV (EC~50~ of 14 and 22 μM, respectively) ([@B15]).

Cationic antimicrobial peptides (AMPs) are another type of peptides that have been considered as potential broad-spectrum antiviral agents. For instance, mucroporin is an AMP found in *Lychas mucronatus* scorpion venom ([@B52]). Mucroporin was then optimized synthetically, generating mucroporin-M1, which was able to inhibit measles virus (MeV), SARS-CoV, and influenza H5N1. Specifically, mucroporin M-1 affected SARS-CoV pseudovirus entry, with EC~50~ of 14.46 μg mL^--1^ and CC~50~ of 61.58 μg mL^--1^, by virucidal activity in HeLa-ACE2 cells ([@B131]). The activity of this synthetic peptide seems to be related to positive charges of the hydrophilic site, which can enhance the interaction with the viral surface, inactivating the viral particle.

Other potential antiviral peptides were selected by Struck and colleges. Through the exploitation of bioinformatics tools, the authors were able to predict sixteen peptides with effective binding onto the receptor-binding domain (RDB) present in S proteins of CoVs. These compounds were then synthesized, and the hexapeptide Tyr-Lys-Tyr-Arg-Tyr-Leu at 14 mM inhibited SARS-CoV and HCoV-NL63 infection in Vero cells without triggering cytotoxicity ([@B208]). This peptide was designed specifically to bind to the site of interaction with S protein and does not interfere with ACE2 receptor activity, so it might be a good candidate for blocking SARS-CoV-2 entry without impairing host metabolism. Taking into consideration that cellular factors such as the Tumor Necrosis Factor-alpha (TNF-α) converting enzyme (TACE) facilitate SARS-CoV entry ([@B85]), it is reasonable to suggest that TACE inhibitors could hinder SARS-CoV infection. In this context, TAPI-2, a compound able to inhibit TACE, has shown potent antiviral activity, promoting a 65% blockade of SARS-CoV entry in HEK-293T cells. However, the compound did not affect the virus titer in *in vivo* assays ([@B84]). The authors suggested that since SARS-CoV attaches to additional receptors such as DC-SIGN and L-SIGN ([@B104]; [@B86]), viral entry might be not be impaired by this molecule.

In addition to amino acid-based inhibitors, monoclonal antibodies (mAbs) have attracted attention due to their use in infectious and chronic disease treatments ([@B80]; [@B88]; [@B164]; [@B53]), overcoming drawbacks caused in polyclonal Abs therapy, such as those related to donor compatibility ([@B142]). Human neutralizing Abs against human CoVs have been generated, targeting S glycoproteins to impair viral entry ([@B21]; [@B179]). Notably, several mAbs were identified as inhibitors of MERS-CoV and SARS-CoV infections both *in vitro* and *in vivo*, protecting cells and animals when administered 24 h prior to or post-infection ([@B134]; [@B257]; [@B3]; [@B196]). The mAbs are developed by merging B lymphocytes and myeloma cells, producing hybridomas capable of recognizing antigens and producing a single Ab class to bind specific epitopes ([@B136]). For that reason, mAb cross-reactivity among different coronaviruses seems to be ineffective ([@B219]). In the particular case of SARS-CoV-2, Wang and coworkers produced mAbs using 51 lineages of SARS-S hybridoma cells and identified 47D11 H2L2-neutralizing Ab through ELISA assays. This antibody was produced using mice cells; therefore, it was further modified to produce a fully human immunoglobulin IgG1, producing the human monoclonal antibody 47D11. The results showed that 47D11 bound to the RBD region and inhibited SARS-CoV-2 entry in Vero cells with an EC~50~ of 0.57 μg mL^−1^ ([@B231]). In this context, this mAb can be used alone or in association with other compounds to treat COVID-19.

Inhibitors of Post-entry Stages of the CoV Replicative Cycle {#S2.SS2}
------------------------------------------------------------

Among the proteins that are pivotal for CoV viral replication are the main proteases (Mpro) such as the chymotrypsin-like protease (3CLpro) and the papain-like proteases (PPL). These enzymes process viral polyproteins and control replicase complex activity ([@B10]), figuring as very attractive targets for drug development against CoVs. Several natural products and synthetic peptides have been reported to inhibit Mpro ([@B45]; [@B229]).

Gan and coworkers used molecular docking methods to select the octapeptide Ala-Val-Leu-Gln-Ser-Gly-Phe-Arg as Mpro inhibitor of SARS-CoV and evaluated its antiviral activity in infected Vero cells. The octapeptide presented an EC~50~ of 2.7 × 10^--2^ mg mL^--1^ and a CC~50~ \> 100 mg mL^--1^, resulting in a selectivity index of over 3,704 ([@B69]). Moreover, five Phe-Phe dipeptide inhibitors (A-E) were designed and selected *in silico* to interact with 3CLpro and showed to be able to protect Vero cells from the cytopathic effect (CPE) caused by SARS-CoV. C analog (JMF1521) was obtained by the condensation of Phe-Phe dipeptide unsaturated ester with cinnamic acid and exhibited the highest activity, with an EC~50~ of 0.18 μM and CC~50~ \> 200 μM ([@B202]). The authors also performed enzymatic assay to evaluate the activity of JMF1521 on 3CLpro and showed that the peptide inhibited the 3CLpro activity with an inhibition constant of 0.52 μM. The results suggested that this analog disposes a rather rigid coplanar structure in the N-terminal motif that results in more effective hydrogen bonds with the enzyme residues ([@B202]).

Another example of a dipeptide-based compound that can act as a protease inhibitor is dipeptidyl EP128533 ([@B256]), which showed antiviral activity against SARS-CoV in Vero cells, with EC~50~ and CC~50~ values of 3.6 and \>100 μM, respectively ([@B256]). In accordance with that study, it was also demonstrated that EP128533 inhibited SARS-CoV with an EC~50~ of 1.4 μg mL^−1^ and CC~50~ \> 100 μg mL^−1^ ([@B55]). However, the compound was not efficient in reducing the effects of viral replication in BALB/c mice ([@B55]). The authors proposed that EP128533 is relatively insoluble and that its lack of activity might be related to a low bioavailability in the animal models.

The dipeptides GC373 (dipeptidyl aldehyde) and GC376 (dipeptidyl bisulfite adduct salt from GC373) were also designed and synthesized as protease inhibitors of the 3CLpro enzyme ([@B115]). Their activity was assessed *in vitro*, and the results showed that GC373 inhibited HCoV-229E (EC~50~ of 0.2 μM), feline infectious peritonitis virus (FIPV, EC~50~ of 0.3 μM), MHV (EC~50~ of 2 μM), transmissible gastroenteritis virus (TGEV, EC~50~ of 0.3 μM), and bovine coronavirus (BCV, EC~50~ of 0.7 μM) ([@B115]). GC376 also inhibited HCoV-229E (EC~50~ of 0.15 μM), FIPV (EC~50~ of 0.2 μM), MHV (EC~50~ of 1.1 μM), TGEV (EC~50~ of 0.15 μM), and BCV (EC~50~ of 0.6 μM). The 3CLpro activity of these compounds against SARS-CoV was also analyzed. GC373 and GC376 inhibited enzymatic activity of SARS-CoV 3CLpro, with inhibition constants of 50% of 3.48 and 4.35 μM, respectively ([@B115]). However, the activity of these compounds was not evaluated using infected cells or animal models. Additionally, the effects of GC373 and GC376 were assessed against feline coronavirus WSU (FCoV-WSU) (EC~50~ values for GC373 and GC376 were 0.15 and 0.40 μM, respectively) ([@B116]). Moreover, the authors described that concomitant treatment with these compounds can improve the antiviral effect against feline coronaviruses and noted that, since the 3CLpro is conserved among CoVs, it might present broad-spectrum activity ([@B116]).

RNA-dependent RNA polymerase (RdRp) also figures as a promising target for antivirals. In viral replication, RdRp is responsible for catalyzing the replication of the viral RNA using a complementary RNA as a template. Therefore, compounds that interfere in this process are excellent drug candidates for treating viral infections ([@B70]). Nucleoside analogs of pyrimidine interfere in uridine triphosphate (UTP) metabolism, directly affecting viral replication ([@B154]), as demonstrated by β-[D]{.smallcaps}-N^4^-hydroxycytidine (NHC), which inhibited SARS-CoV (EC~50~ of 10 μM and CC~50~ \> 100 μM) and HCoV-NL63 (EC~50~ of 400 nM and CC~50~ \> 100 μM) ([@B17]). NHC presented a potent antiviral activity against SARS-CoV-2 in infected Vero (IC~50~ of 0.3 μM and CC~50~ of \> 10 μM) and Calu-3 cells (IC~50~ of 0.08 μM and CC~50~ \> 100 μM) ([@B199]). The authors assessed the broad-spectrum antiviral activity of NHC against MERS-CoV (IC~50~ 0.024 μM) and SARS-CoV (IC~50~ 0.14 μM) ([@B199]) and also evaluated the NHC effect in SARS-CoV- and MERS-CoV-infected mice. NHC improved pulmonary function and decreased viral load in lung, and the authors proposed that NHC might be useful for emerging CoVs. Another pyrimidine analog with potential antiviral activity is 6-azauridine, which inhibited HCoV-NL63 replication in LLC-MK2 cells with an EC~50~ of 32 nM and CC~50~ of 80 μM ([@B174]).

Ribavirin is a synthetic nucleoside analog of guanosine used for the treatment of patients chronically infected by the hepatitis C virus (HCV) ([@B172]). The antiviral activities of ribavirin against several RNA viruses have been described, and it also presents broad-spectrum antiviral activities for CoVs ([@B31]; [@B200]). Its activities were described for SARS-CoV *in vitro* (EC~50~ of 20 μg mL^−1^ and CC~50~ \> 200 μg mL^−1^) ([@B187]). Nevertheless, no viral load reduction was observed *in vivo* when employing BALB/c mice ([@B16]). The *in vitro* decrease of ribavirin efficacy was demonstrated to be associated with the excision of its nucleoside analogs by conserved coronavirus proofreading mechanisms ([@B68]). Moreover, ribavirin showed good results for the treatment of critical MERS-CoV patients ([@B9]), and the combined treatment of ribavirin with type I Interferons (IFN-I) in primate models improved MERS disease symptoms ([@B65]). Although ribavirin has been given as part of treatment regimens for SARS and MERS patients, meta-analyses of cases of study have found limited efficacy of its activities in treating patients with highly pathogenic coronavirus respiratory syndromes ([@B152]).

What is more, a nucleoside analog based on the acyclic sugar scaffold of acyclovir showed antiviral potential against coronaviruses ([@B213]). Peters and contributors demonstrated that this compound has powerful antiviral activity against MERS-CoV (EC~50~ and CC~50~ of 23 and 71 μM, respectively) and HCoV-NL63 (EC~50~ and CC~50~ of 8.8 and 120 μM, respectively) ([@B163]). However, the authors did not suggest mechanisms by which this analog impairs viral replication, leaving open to question whether it acts like its precursor acyclovir, impairing viral replication or by an alternative mechanism of action.

In terms of other drug options for the post-entry stages of the viral replicative cycle, it is possible to report the activities of Niclosamide, a drug used in antihelminthic treatment ([@B110]). Niclosamide presented antiviral activity on post-entry steps of SARS-CoV infection in Vero cells, with an EC~50~ of 1--3 μM and CC~50~ of 250 μM ([@B245]). Similarly, this compound suppressed the cytopathic effect of SARS-CoV at a concentration \<1 μM and inhibited viral replication with an EC~50~ value of less than 0.1 μM in Vero E6 cells ([@B238]). Both authors suggested that Niclosamide impairs post-entry steps. However, this effect seems to not be related to an interaction with 3CLpro.

An additional potential compound is mycophenolic acid (MPA), an antibiotic derived from penicillium fungal species ([@B171]), which inhibited MERS-CoV replication in Vero cells with an EC~50~ of 2.87 μM ([@B87]). However, MPA was not active against SARS-CoV in either *in vitro* or *in vivo* assay ([@B16]). The data suggested that MPA inhibits the enzyme IMP dehydrogenase, inducing apoptosis on alveolar macrophages and consequently inhibiting or suppressing cellular immune responses that are important for preventing or limiting viral infection ([@B16]).

Bananins, on the other hand, are a class of adamantane-based compounds conjugated with a pyridoxal moiety (vitamin B6) ([@B112]). These molecules showed effective inhibition of SARS-CoV in FRhK-4 cells, with EC~50~ \< 10 μM and CC~50~ of 390 μM. On the basis of both time addition and ATPase assays, the authors proposed that the action of bananin is mainly on the post-entry step of virus replication and may be related to an effect on the helicase function and/or on components of cellular pathways ([@B214]).

Finally, the nonstructural protein 10 (nsp10) of CoVs was described as being responsible for a stimulatory effect on nsp16, a classical S-adenosylmethionine-dependent (nucleoside-2'-*O*)-methyltransferase that acts in RNA binding or catalysis. The peptide TP29 was designed as a ligand to MHV nsp10 and presented broad-spectrum activity, inhibiting SARS-CoV (EC~50~ of 200 μM) and MHV (EC~50~ of 60 μM) replication in infected cell lines ([@B235]). The authors also assessed TP29 activity in MHV infected mice and demonstrated that treatment improved survival, decreased viral load in liver, and induced type 1 IFN. Based on these data, it was suggested that TP29 impaired nsp10/nsp16 2'-*O*-MTase activity, dysregulating the genome replication process.

Looking Toward Host Machinery: A Different Approach to CoV Treatment {#S2.SS3}
--------------------------------------------------------------------

Targeting the host process during viral infection figures as a promising alternative for drug development and can play an important role in abrogating viral replication ([@B191]; [@B221]). Nitazoxanide is a broad-spectrum antiviral agent exploited for the treatment of, for instance, influenza A and B viruses, as well as Ebola virus (EBOV) ([@B184]; [@B103]), with its activity related to the interference in host-regulated pathways during viral replication ([@B185]). *In vitro* studies demonstrated that Nitazoxanide was able to inhibit MERS-CoV in LLC-MK2 cells, with an EC~50~ of 0.92 μg mL^--1^. The authors suggested that nitazoxanide affects pro-inflammatory cytokines and suppresses their overproduction ([@B185]).

Another host-target compound is Saracatinib (AZD0530), a tyrosine kinase (SFK) inhibitor. This compound suppressed the early stages of the MERS-CoV replicative cycle in Huh7 cells (EC~50~ of 2.9 μM and CC~50~ \> 50 μM), possibly by affecting the SFK pathways ([@B203]). SFK possesses a central function in signaling pathways such as ERK/MAPK and PI3K/AKT ([@B216]), which are strictly related to CoV infection. Therefore, SFK inhibition might promote viral clearance and can be used in association with other drugs ([@B203]).

Moreover, Cyclosporin A (CsA), a peptide with activity on the cyclophilin family of host enzymes (isomerases that act as chaperones) ([@B170]; [@B54]), inhibited SARS-CoV (100% inhibition at 16 μM), HCoV-229E (75% inhibition at 16 μM), and MHV (100% inhibition at 16 μM) in human and animal infected cell culture. CsA presented broad-spectrum antiviral activity against CoVs, and it seems to interfere with genome replication/transcription during CoV infections ([@B59], [@B58]; [@B165]). Alisporivir, a non-immunosuppressive cyclosporin A analog, inhibited the replication of SARS-CoV in Vero E6 infected cells at low-micromolar concentrations (EC~50~ of 8.3 μM; CC~50~ \> 50 μM). This compound also showed broad-spectrum anti-CoV activity, inhibiting MERS-CoV EMC/2012 (EC~50~ of 3.6 μM), MERS-CoV N3/Jordan (EC~50~ of 3 μM), and SARS-CoV MA-15 (EC~50~ of 1.3 μM) *in vitro* ([@B56]). However, the authors demonstrated that Alisporivir did not enhance survival in CoV-infected mice ([@B56]).

Other biomolecules that are promising as drug antivirals are interference RNAs (iRNAs). These macromolecules are small non-coding RNAs associated with controlling the expression of genetic information ([@B243]) and have been described as promising candidates for the treatment of hepatitis B virus (HBV), HCV, HIV, and human T-cell lymphotropic virus (HTLV) infections ([@B140]; [@B195]; [@B190]). Short interference RNAs (siRNAs) were described as being effective for *in vitro* antiviral treatment of FIPV, a type of FCoV ([@B145], [@B146]). Most recently, Li and colleagues designed and synthesized siRNAs that targeted the M and N genes of swine and porcine coronaviruses (SECoV and PDCoV, respectively). These siRNAs inhibited up to 99% of the expression of these proteins in both Vero and LLC-PK1 infected cells ([@B130]). Additionally, synthetic siRNAs targeting the structural proteins E, M, and N of SARS-CoV have also been developed and showed reductions of the target gene expressions in Vero cells ([@B201]). Moreover, siRNAs targeting the structural proteins 7a, 7b, 3a, 3b, and S reduced SARS-CoV progeny in Vero cells by approximately 70% ([@B6]). The different authors propose that treatment with siRNAs can improve treatment-resistance among viruses and that these molecules can be designed to target multiple proteins, aiming at broad-spectrum activity.

Ongoing Clinical Evaluations With Candidate Drugs Against SARS-CoV-2 {#S2.SS4}
--------------------------------------------------------------------

The current situation of COVID-19 pandemic has accentuated the urgency of the demand for effective treatments. Based on previous data concerning activities against other viruses and empirical knowledge from treatments used in case reports, several drugs have entered clinical trial phases to access their therapeutic potential against SARS-CoV-2. In this section, we discuss the current knowledge on the most promising candidates for the treatment of COVID-19. Data for these drugs are summarized in [Table 2](#T2){ref-type="table"}.

The nucleoside analog Remdesivir (GS-5734) is a monophosphoramidate prodrug that has been described as having antiviral activity against the EBOV in non-human primates ([@B236], 57). Its activity was assessed in human airway epithelial (HAE) cells infected with SARS-CoV (EC~50~ of 0.069 μM and CC~50~ \> 10 μM) and MERS-CoV (EC~50~ of 0.074 μM and CC~50~ \> 10 μM) and was demonstrated to inhibit RdRp of these viruses. Also, GS-5734 reduced infectious virus production of bat CoV by 1.5 to 2.0 log~10~ in HAE cells and reduced virus titers and virus-induced lung pathologies in a SARS-CoV assay *in vivo* ([@B197]). This compound also reduced the severity of MERS-CoV disease, virus replication, and damage in the lungs of rhesus macaques ([@B60]). The clinical efficacy of GS-5734 has been assessed by several clinical trials in different countries like France (NCT04365725), Canada (NCT04330690), and the United States (NCT04292899), which have been conducted based on the first reported treatment of COVID-19 with Remdesivir in Washington, United States ([@B94]). In the first findings from Wang and coworkers, which were from a randomized, double-blind, multicenter, and placebo-controlled trial with 255 patients, Remdesivir did not present significant antiviral effects against SARS-CoV-2, nor did it improve clinical outcomes ([@B234]). To date, there are several active clinical trials registered in the PubMed database involving this compound. However, most of them presented no conclusive outcomes.

Another two candidates are Lopinavir and Ritonavir, which are protease inhibitors used in association to treat HIV infections ([@B51]; [@B149]). Lopinavir demonstrated antiviral activities, protecting cells from MERS-CoV infection (EC~50~ of 8 μM) and reducing viral loads in animal assays ([@B57]; [@B117]). Ritonavir also demonstrated anti-MERS-CoV activities with an EC~50~ of 24.9 μM ([@B198]). It is important to point out that these results do not agree with another work that was unable to demonstrate *in vitro* antiviral activity of Lopinavir against MERS-CoV ([@B31]). In clinical assays for MERS-CoV, the association of Lopinavir with Ritonavir reduced adverse clinical outcomes and viral load in infected patients ([@B198]; [@B250]). In particular, for SARS-CoV, Lopinavir and Ritonavir presented a low to medium antiviral activity *in vitro*, and *in vivo* assays have not been performed yet ([@B250]). In addition, Lopinavir and Ritonavir played an important role in the clinical outcome of SARS-CoV-infected patients by reducing symptoms and the period of hospitalization, representing a possibility for the treatment of SARS-CoV-2 ([@B43]). Cao and collaborators conducted a randomized clinical trial with 199 patients with severe COVID-19 ([@B27]). Treatment of the patients with the association Lopinavir/Ritonavir did not improve symptoms, nor impaired detectable viral RNA when compared to standard care (supplemental oxygen, noninvasive and invasive ventilation, antibiotic agents, vasopressor support, renal-replacement therapy, and extracorporeal membrane oxygenation). Additionally, the treatment generated relevant adverse effects in some of the patients ([@B27]). The authors proposed that the low efficacy of Lopinavir with Ritonavir might be associated with the time of administration, since individuals that were treated at the onset of the disease had improved clinical results ([@B27]). Later, it was shown that the association of lopinavir and ritonavir with interferon-β1 and ribavirin to treat mild to moderate COVID-19 patients alleviated symptoms and decreased the durations of viral infection and hospital stay ([@B100]). This might be related to their inducing cellular immune response, impairing virus replication.

The type 1 interferons (IFN-I) have also been employed in clinical trials. These proteins belong to the cytokine family and are associated with the immune response in viral infections, thus playing major roles in antiviral immunity due to their immunomodulatory properties ([@B189]). Therefore, they are commonly employed in the treatment of several diseases such as Hepatitis C ([@B121]). There are two subtypes of IFN-I, alpha (IFN-α) and beta (IFN-β) ([@B189]). IFN-β is associated with more potent activity ([@B32]) and is therefore capitalized on in the treatment for multiple sclerosis patients ([@B13]). Due to its more potent inhibition profile, it was associated with potent antiviral effects against SARS-CoV, MERS-CoV, MHV, and HCoV-229E *in vitro* and *in vivo* ([@B206]; [@B226]; [@B89]; [@B64]; [@B32]). IFN-β, in particular, has a protective effect in endothelial cells, up-regulating CD73 and consequently stimulating the anti-inflammatory molecules and maintenance of endothelial barrier ([@B19]; [@B188]). However, a clinical trial with 301 patients showed that this effect was not sufficient to decrease mortality in SARS patients ([@B178]). Therefore, in SARS-CoV-2, IFN-β has been associated with other drugs in clinical trials, improving outcomes in COVID-19 patients as in lopinavir or ribavirin ([@B100]).

COVID-19 patients with mild to severe symptoms can develop hyperinflammation and hypercytokinaemia, which can lead to multiple organ failure and death ([@B147]). The employment of corticosteroids has shown to be an alternative for overcoming the cytokine storm and hyperinflammation due to its activities on immune cells ([@B242]). Such a capitalization was previously reported in SARS-CoV patients during the 2002--2003 epidemic ([@B40]). For SARS-CoV-2, corticosteroids can improve the clinical condition of patients, reducing hyperinflammation and the development of ARDS, with faster improvement of symptoms ([@B233]; [@B253]). However, contrasting data concerning the efficacy of these drugs was described recently, showing that corticosteroids did not improve symptoms in COVID-19 patients ([@B253]). Moreover, dexamethasone emerged as a potential drug for treating COVID-19 patients, as shown by the results of a randomized, controlled, open-lab, and multicenter trial that assessed the effects of dexamethasone in 454 patients, described to date in pre-print findings ([@B95]). Data suggested that dexamethasone reduced death in one-third of patients in invasive mechanical ventilation and one-fifth of patients in non-invasive oxygen mechanical ventilation. However, it did not impair mortality in patients with no respiratory support ([@B95]). Other trials have been conducted, such as NCT043274011, but considering the preliminary results, the WHO suggested that treatment with dexamethasone may be applied during the third phase of COVID-19, when the hyperinflammation is determined, and respiratory support is needed.

Another antiviral drug assayed toward SARS-CoV-2 is Umifenovir, a licensed antiviral exploited for the prophylaxis and treatment of influenza viruses (Arbidol), which demonstrated good pharmacokinetics when absorbed by the organism ([@B169]). This drug has an antiviral effect against SARS-CoV *in vitro* at 50 μg mL^--1^ ([@B113]). Lian and coworkers coordinated an observational study with 81 patients with moderate to severe SARS-CoV-2 infection ([@B133]) that demonstrated that Umifenovir neither shortened the hospitalization period nor improved prognosis in infected patients ([@B133]).

Broad-spectrum drugs used against parasitic infections such as Ivermectin ([@B24]; [@B124]) have also been investigated due to their antiviral activity against Dengue virus (DENV), Influenza A viruses, Chikungunya virus (CHIKV), and HIV ([@B215]; [@B78]; [@B225]; [@B22]). The activity of Ivermectin is based on impairing several stages of viral replication, for instance, interfering with nonstructural proteins ([@B225]). Caly and collaborators assessed the effect of Ivermectin on SARS-CoV-2 replication in Vero cells, showing that, at 5 μM, the compound presented no toxicity to cells and inhibited up to 99% of viral replication by a possible antiviral effect on viral release, which is consistent with previous data on its activity against other RNA viruses ([@B215]; [@B22]). Clinical trials have been conducted in different medical centers in Argentina (NCT04381884), Mexico (NCT04391127), Spain (NCT04390022), and the United States (NCT04374279) to assess the clinical implications of the use of Ivermectin for COVID-19. However, to the best of our knowledge, there are no published results on this topic. NCT04343092, a phase 1 clinical trial in Iraq, was conducted to its completion and evaluated the efficacy of Ivermectin in COVID-19 patients, so the results might be published soon.

According to Guan and colleagues, approximately 15.7% of Chinese patients with COVID-19 developed severe pneumonia and cytokine release syndrome (CRS), an important factor leading to rapid progression of the disease ([@B42]; [@B83]). In this context, one of the key cytokines involved in infection-induced cytokine storm is interleukin 6 (IL-6) ([@B192]; [@B254]). Tocilizumab is an IL-6 receptor antagonist approved by the US FDA for the treatment of severe CRS ([@B81]) and figures as an interesting drug to treat the cytokine storm caused by SARS-CoV-2 ([@B255]). The treatment of patients with severe COVID-19 with Tocilizumab presented no complications in the 21 assisted patients, with an average age of 56.8 ± 16.5 and no history of illness deterioration or death. Thus, it immediately improved the clinical outcome and appeared to be an effective treatment for reducing mortality ([@B247]). Another study employing the treatment of COVID-19 patients with Tocilizumab for 14 days reinforced these observations. The treatment was observed to cause an effective decrease in inflammatory markers, radiological improvement, and a reduction in ventilatory support requirements for these patients ([@B7]). Additionally, Toniati and collaborators administered Tocilizumab in 100 patients in Italy (average age of 62 years old) who had been diagnosed with COVID-19 pneumonia and ARDS and required ventilatory support. Overall, at 10 days of follow-up, the respiratory condition was improved or stabilized in 77% of the patients, and, based on these data, the response to this drug in patients with severe COVID-19 was rapid, sustained, and associated with significant clinical improvement ([@B218]).

Chloroquine is a 9-aminoquinole that increases the pH in acidic vesicles ([@B144]) and possesses antiviral activities against HIV and other viruses ([@B102]; [@B8]). Chloroquine was described as an entry inhibitor of SARS-CoV infection in Vero cells and prevented cell-to-cell spread of the virus ([@B228]). Furthermore, it affected the entry and post-entry stages of the replicative cycle of FCoV in *Felis catus* cells and monocytes. Additionally, an *in vivo* study in cats demonstrated that treatment with chloroquine improved the clinical score of treated groups when compared to the untreated group ([@B211]). Chloroquine also had its anti-CoV activities tested in Vero cells (EC~50~ of 5.47 μM) ([@B232]; [@B251]). Despite the performance of chloroquine *in vitro*, clinical studies conducted in China and France showed contradictory clinical data ([@B34]; [@B38]; [@B71]; [@B151]). Gao and collaborators indicated that chloroquine phosphate was recommended to treat COVID-19-associated pneumonia only during urgent clinical demand because of its antiviral and anti-inflammatory activities ([@B71]). Hydroxychloroquine is an analog of chloroquine that was described as having antiviral activity, inhibiting SARS-CoV-2 *in vitro* with an EC~50~ of 0.72 μM ([@B137]; [@B251]). In clinical trials, an open-label non-randomized study by Gautret and colleagues affirmed that hydroxychloroquine reduced symptoms from SARS-CoV-2 patients and that association with azithromycin could reinforce its effects ([@B73]). However, these results have been questioned. The study had a small sample size, and there were limitations in the methodologies ([@B106]).

Recent studies have been contradicting the safety of chloroquine and hydroxychloroquine use, as these drugs presented severe side effects that interfered with their clinical use, even during short-course therapies ([@B106]; [@B137]). Apart from the mild adverse effects, such as pruritus, nausea, and headache, these drugs can predispose patients to life-threatening arrhythmias, an effect that may be enhanced by concomitant use of azithromycin ([@B41]). Both chloroquine and hydroxychloroquine interfere with ventricular repolarization, leading to prolongation of the cardiac QT interval and an increased risk of torsades de pointes (TdP), which is a risk especially for patients with cardiac disease, for children, or for those taking other drugs that delay repolarization ([@B155]; [@B173]; [@B106]; [@B223]). Others possible types of damage are hypoglycemia, even in non-diabetic patients ([@B222]; [@B63]); neuropsychiatric effects, including agitation, insomnia, confusion, paranoia, depression, psychosis, and suicidal ideation ([@B150]); hypersensitivity reactions, such as severe cutaneous adverse reactions ([@B23]; [@B75]); and drug--drug interactions, which are improved by genetic variability (genetic polymorphisms of hepatic cytochrome P450 enzyme 2D6 (CYP2D6), responsible for chloroquine metabolization) ([@B119]; [@B126]). There is a lack of reliable information on target concentrations or doses for COVID-19, and so doses that proved effective and safe in malaria for both adults and children are considered for the treatment ([@B205]). Recently, the WHO stopped the hydroxychloroquine arm of the Solidarity trial to treat COVID-19 based on an absence of effectiveness in reducing the mortality of hospitalized COVID-19 patients ([@B241]). Besides, the FDA also cautioned against the administration of hydroxychloroquine or chloroquine in COVID-19 patients, mainly due to the risk of heart rhythm issues ([@B66]). From these results, it is evident that the use of these drugs for COVID-19 requires further investigation.

An alternative treatment for COVID-19 is the utilization of convalescent plasma (CP) ([@B35]). This treatment refers to plasma therapy based on plasma or plasma derivatives, obtained from donors who were previously infected and have developed antibodies. This plasma/derivative is, in its turn, transfused into individuals with acute SARS-CoV-2 infection ([@B72]; [@B25]). Even though the mechanism of action of convalescent plasma therapy is not fully understood, it presented great results in the treatment of patients with SARS during the SARS-CoV outbreak in Hong Kong in the early 2000s ([@B39]). It is possible that the efficacy of CP therapy is due to the fact that the antibodies from convalescent plasma might suppress viremia ([@B35]). Duan and colleagues reported CP transfusion to rescue ten severe cases of SARS-CoV-2 adult patients. The study showed that one dose (200 mL) of CP significantly increased or maintained the neutralizing antibodies at a high level, leading to the disappearance of viremia in 7 days. Clinical symptoms rapidly improved within 3 days, and radiological examination showed varying degrees of absorption of lung lesions within 7 days. According to these results, CP can also provide a promising rescue option for severe COVID-19 ([@B62]). However, the author suggested key points to guarantee the effectiveness of CP therapy: Ab titers and the treatment time point. Firstly, taking into consideration previous knowledge from MERS-CoV CP therapy, Abs in plasma donor must have a titer equal or higher of 1:80 ([@B120]). This titer is only found in recently recovered patients, since antibody levels decrease 4 months after the disease. Secondly, patients receiving CP treatment prior to 14 days post-infection responded better than patients treated after 14 days ([@B62]).

Perspectives {#S3}
============

This review aimed to summarize and discuss data from the literature regarding compounds that possess anti-CoVs activities and that could be further exploited for the treatment of human and animal CoVs. Furthermore, we described ongoing clinical trials for SARS-CoV-2 in order to elucidate the current findings and discussed the relevant features concerning candidate drugs against SARS-CoV-2.

As previously mentioned, most human-related CoVs emerged by zoonotic transmission from animals ([@B101]; [@B49]; [@B180]). Since *Coronaviridae* seem to have a very well conserved genome and structures among their viruses ([@B98]; [@B82]; [@B249]; [@B141]), it is possible to hypothesize that compounds with antiviral activities against different human and/or animal CoVs (broad-spectrum activity) could be potential candidates for SARS-CoV-2 treatment. In a less optimistic scenario, the chemical structures of such compounds and their pharmacological outcomes have the potential to set some light on the drug design of possible anti-SARS-CoV-2 drugs.

Among the strategies for drug design, targeting host-immune factors or using iRNAs figure as promising alternatives for antiviral drug development. Also, the exploitation of *in silico* studies for drug screening to seek specific targets, as well as for a better comprehension of their interactions with viral biomolecules, has been shown as a promising tool for expediting drug development. By narrowing down the number of drug candidates, *in silico* studies have the potential to avoid the laborious and generally costly synthesis of many of these compounds ([@B128]; [@B227]). Nevertheless, several predicted compounds in the literature have only been screened by *in silico* and/or interaction assays ([@B36]; [@B107]; [@B127]; [@B115]; [@B12]; [@B14]), which ultimately hinders the proper assessment of the antiviral activities of the compounds. Therefore, it is imperative that these studies be associated with *in vitro* and *in vivo* assays in order to confirm the predicted activities in biological models and also to evaluate pharmacological outcomes ([@B156]). Therefore, this review encompassed only compounds that have been evaluated by, at least, *in vitro* models ([Table 1](#T1){ref-type="table"}).

In this context, from the molecules and drugs described as having *in vitro* activity, we highlighted the most promising to suggest further evaluation using *in vivo* systems of CoV infection, especially SARS-CoV-2 infection. The compounds are: NAAE, Glycyrrhizin, 2-acetamido-α-[D]{.smallcaps}-Glucopyranosylamine derivative, Tetrahydroquinoline oxocarbazate (CID 23631927), SSAA09E1, 2 and 3, Emodin, Eremomycin 27 and 29, Mucroporin-M1, Monoclonal antibody 47D11, AVLQSGFR, Phe-Phe dipeptide inhibitor C (JMF1521), GC373 and 376, 6-azauridine, Acyclic sugar scaffold of acyclovir, and Bananins. As described above, these compounds were capable of significantly impairing CoV infection in cell cultures and might enable important progress into the treatment of described CoVs as well as viruses that might be responsible for future viral outbreaks.

Here, we also described compounds that were evaluated *in vivo* to elucidate their role in the pathogenesis of CoVs as well as to assess possible adverse effects. It is important to emphasize that there is a lack of *in vivo* model assays, representing a delay in anti-CoV drug development, which directly impacts the SARS-CoV-2 pandemic. Here, we identified some studies that employed animal models, such as in Balb/c mice and C57BL/6, to evaluate the antiviral effect of compounds in CoV infection ([@B46]; [@B187]; [@B16]; [@B256]; [@B55]; [@B87]). The *in vivo* assays allow the gathering of knowledge regarding the ADMeTox profile of these compounds in complex biological systems, the viral titers in different organs, host immune responses to the infection, and also potential tissue damage caused by the viruses in the presence or absence of candidate drugs, which represents an advance in understanding pathologies caused by viral infections ([@B1]). It is also important to emphasize that protocols used in studies of animal-related viruses are not easily translated onto human CoVs, since these viruses are classified to different biological safety levels, representing a risk of infection to scientists ([@B18]; [@B29]). Additionally, the pathologies induced by animal CoVs are mostly related to gastrointestinal symptoms, differently to what is observed for human-related CoVs, which mostly affect the upper respiratory system ([@B162]; [@B49]). The development of refined and secure protocols to study SARS-CoV-2 infection and its treatment options is required. Bearing in mind the obstacles cited above, assessment of the effect in animal models and further translation to humans remains one of the main challenges.

However, some of the studies were able to assess the antiviral effects of some compounds *in vivo*. The most relevant compounds we propose that may represent immediate candidates to clinical trials, considering the urgency of COVID-19, are Griffithsin (GRFT), β-[D]{.smallcaps}-N^4^-hydroxycytidine (NHC), TP29, Cyclosporin A (CsA), Alisporivir, iRNAs, Saracatinib, Tizoxanide, Nitazoxanide, Niclosamide, and Ribavirin. These compounds abrogated CoV infection *in vitro* and *in vivo* and improved the symptoms and survival of animals. In addition, Saracatinib, Tizoxanide, Nitazoxanide, Niclosamide, and Ribavirin are molecules licensed to treat diseases such as those from viral and helminthic infections or Alzheimer's disease, representing possibilities for clinical trials as repurposed drugs.

Regarding clinical trials, most drugs discussed in this review presented adverse effects such as nausea, headache, diarrhea, urticaria, pathologies related to the gastrointestinal system, and interference with liver enzymes ([@B186]; [@B211]; [@B183]; [@B250]). Remdesivir, Lopinavir and Ritonavir, and Umifenovir are drugs employed for the treatment of other viral infections such as EBOV and SARS-CoV, but, in the clinical trials with COVID-19 patients, these treatments did not reduce symptoms and/or decrease viral load. Tocilizumab, Chloroquine, and Hydroxychloroquine have been demonstrated to inhibit SARS-CoV-2 *in vitro* and, in some clinical trials, reduced COVID-19 symptoms, the period of hospitalization, and the viral load in patients despite the strong adverse effects of Chloroquine ([Table 2](#T2){ref-type="table"}). Even so, recent studies are contradicting the safety profiles of Chloroquine and Hydroxychloroquine, since they might cause arrhythmia in patients, representing risk for a considerable number of patients ([@B106]).

Ongoing studies have been evaluating IFN-β and Ivermectin as treatments against COVID-19. IFN- β can be associated with other drugs, collaborating to control immune response against the viral infection ([Table 2](#T2){ref-type="table"}). On the other hand, corticosteroids, such as dexamethasone, sound promising, but there are some issues related to their use. These compounds induce immunosuppression and, when administered during initial phases (viral replication), might dysregulate T-cell production and activation of B cells for antibody secretion, which are essential for viral clearance ([@B48]; [@B74]). Furthermore, convalescent plasma therapy is an alternative approach that presented positive effects in studies on SARS-CoV-2/COVID-19 patients. However, its safety is not well defined due to donor-dependent variability and compatibility (antibody titers and other factors vary among donors), which might cause severe adverse effects in lung and cardiovascular system and, in some cases, may even transmit diseases ([@B181]).

Despite the finding regarding these drugs, it is important to take some aspects into consideration: i) the trials were generally conducted with a significant number of patients in each study, but potentially not enough to expand the results to public healthcare; ii) some of the studies were observational, which means they were based on public data that may not be well documented, leaving information gaps about particular health issues; additionally, the outcomes in patients are defined by their own circumstances, and not by an investigator; iii) some studies were not placebo-controlled and double-blind, so the placebo effect cannot be discarded ([@B111]; [@B90]); iv) the trials were conducted by selecting a group of COVID-19 patients, considering mild, moderate or severe cases, and different outcomes can be expected in each situation since viral load, the progression of the disease, and immune response are additional factors ([@B111]; [@B90]). Therefore, drugs with no effect in severe cases cannot be rejected as a possible treatment in mild to severe cases. When these aspects are not considered, the investigators might be open to commiting type I or II error in trials ([@B111]; [@B90]). For that matter, it is also important to consider that SARS-CoV-2 is a new virus and that we currently have limited knowledge about its physiopathology. Finally, the development of new treatment options is critical, and efforts have been focused on targeting therapies that aim to improve patient outcome by increasing antiviral activity associated with minimal toxicity.

Another point to be considered in CoV treatment is that RNA viruses are known to have high levels of mutations (error rate) in the replication process ([@B70]). This can result in resistance to antiviral treatment, as observed for HIV, HCV, and Influenza viruses ([@B125]; [@B129]; [@B159]; [@B212]). A recent study in pre-print pointed to the genomic variability of SARS-CoV-2 and the intra-patient capacity of polymorphic quasispecies, which may offer resistance to antiviral drugs ([@B109]). In addition, previous studies demonstrated that the use of Chloroquine analogs for decades against malaria has established chloroquine-resistant Plasmodium strains ([@B207]; [@B8]; [@B4]). Due to the beneficial immunomodulatory effects of analogs on the severe inflammatory complications of several viral diseases, such as HIV and SARS-CoV infections, these drugs have been tested indiscriminately ([@B102]; [@B8]). However, there is a possibility that prophylactic exposure to pro-apoptotic chloroquine drugs caused natural selection for strains of viruses and other parasites that have enhanced anti-apoptotic abilities ([@B160]). Despite the side effects, the wide use of some drugs during the SARS-CoV-2 pandemic might raise concerns regarding the emergence of resistant viral strains in the future, and we emphasize the lack of information on the resistance associated with these drugs in the treatment of viral infections.

Conclusion {#S4}
==========

The spread of SARS-CoV-2 worldwide is classified as a pandemic and represents a threat to global public health. By July 4, 2020, SARS-CoV-2 had infected 10,922,324 people and had caused 523,011 deaths around the world ([@B240]). In this context, compounds described to possess antiviral activity against human and/or animal coronaviruses could provide relevant information for the development of novel SARS-CoV-2 treatments. Herein, we presented and discussed the most promising compounds that can figure as possible candidates for clinical trials. Moreover, ongoing clinical trials evaluating possible COVID-19 therapies were also highlighted.

From what was presented in this review, a plethora of different potential compounds can be capitalized as possible drugs or even set points for further drug development seeking to mitigate the SARS-CoV-2/COVID-19 outbreak. However, time, resources, and new experimental protocols are essential for advancing an efficacious treatment. In addition, and despite the urgency of treatment protocols, it is important to point out the striking need for the establishment of fail-proof regulatory initiatives that could prevent impacts on the healthcare of patients that could, otherwise, be avoided by a more stringent control.

In this context, this review describes drugs that might be overlooked for future analysis and could possibly become effective antiviral treatments. As a final remark, we conclude that, to date, there is no "one hundred percent" effective antiviral therapy against SARS-CoV-2/COVID-19 and that further research is needed to achieve the best therapeutic protocol, which may not be based on a unique drug but rather on a combination of active antivirals.
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